Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Nrx pharmaceuticals inc save search
RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION
Published: 2022-08-22 (Crawled : 17:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: -4.24%
H: 4.42%
C: 0.29%
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -3.02%
H: 5.38%
C: -0.65%
tentative therapeutics
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: -9.48%
H: 4.19%
C: -39.05%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: -40.54%
H: 20.91%
C: -15.45%
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -38.37%
H: 1.11%
C: -32.16%
covid-19 collaboration aviptadil health
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
Published: 2022-04-22 (Crawled : 09:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: -2.1%
H: 3.39%
C: -0.89%
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -15.09%
H: 1.67%
C: -5.56%
designation collaboration aviptadil therapy
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
Published: 2022-01-04 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: 8.45%
H: 6.1%
C: 6.1%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 10.09%
H: 0.0%
C: 0.0%
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 6.8%
H: 0.0%
C: 0.0%
aviptadil application patent collaboration
NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other Regions
Published: 2021-12-06 (Crawled : 14:30) - globenewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -1.09%
H: 0.0%
C: 0.0%
israel phase 2 europe phase 2b trial vaccine brilife
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
Published: 2021-10-15 (Crawled : 09:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -6.63%
H: 2.97%
C: -7.73%
covid disease treatment aviptadil infectious disease positive collaboration respiratory
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
Published: 2021-10-13 (Crawled : 09:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 43.85%
H: 2.99%
C: -2.78%
collaboration aviptadil commercialization
Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)
Published: 2021-09-28 (Crawled : 08:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -1.49%
H: 0.81%
C: -4.24%
covid collaboration aviptadil
Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
Published: 2021-07-28 (Crawled : 09:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -3.24%
H: 8.08%
C: -6.18%
collaboration merge authorized aviptadil emergency use authorization
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
Published: 2021-07-23 (Crawled : 09:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 22.31%
H: 0.0%
C: 0.0%
collaboration aviptadil commercialization
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
Published: 2021-07-20 (Crawled : 09:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -5.01%
H: 1.19%
C: -12.24%
covid collaboration aviptadil
NRx Pharmaceuticals to Lead Development of COVID-19 Medicines and Vaccines in Central Europe and the Caucasus Region in Collaboration with the Lugar Institute and Cromos Pharma
Published: 2021-05-26 (Crawled : 15:15) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 0.38%
H: 0.0%
C: -6.38%
covid europe collaboration vaccine
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.